CLBIO — Corline Biomedical AB Balance Sheet
0.000.00%
- SEK509.41m
- SEK501.09m
- SEK9.78m
Annual balance sheet for Corline Biomedical AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 8.9 | 41.6 | 26.2 | 17 | 17.7 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.67 | 2.77 | 8.47 | 5.22 | 2.63 |
| Prepaid Expenses | |||||
| Total Current Assets | 11 | 44.8 | 36 | 23.8 | 21 |
| Net Property, Plant And Equipment | 0.073 | 0.182 | 0.28 | 0.314 | 0.219 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 58.5 | 102 | 102 | 100 | 94.8 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.24 | 9.43 | 7.19 | 6.79 | 7.85 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 6.24 | 9.43 | 7.19 | 6.79 | 7.85 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 52.2 | 92.2 | 94.6 | 93.3 | 86.9 |
| Total Liabilities & Shareholders' Equity | 58.5 | 102 | 102 | 100 | 94.8 |
| Total Common Shares Outstanding |